Company: MIRA
Filing Date: 2025-09-11
Form Type: 8-K
Source: 0001493152-25-013100
Chunk: 1

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-09-11
Form: 8-K
Item: Item 5.02
Chunk 1
---
 $5 million in cash
or assets to MIRA. Independent valuation analyses conducted by Moore Financial Consulting assigned enterprise values of approximately
$30.5 million for SKNY (based on a risk-adjusted net present value of SKNY-1) and $30 million for MIRA, supporting a combined enterprise
value of more than $60 million for the merged entity. The Company expects the transaction to close shortly, subject to customary closing
conditions.

The
final voting results were as follows:

Proposal
1

The
Company’s stockholders approved the issuance of shares of MIRA Common Stock or other securities of MIRA pursuant to the Merger
as defined below, which will represent (or are convertible into) more than 20% of the shares of MIRA Common Stock outstanding immediately
prior to the Merger, pursuant to Nasdaq Listing Rule 5635(a), based on the voting results set forth below.

   Votes For      Votes Against      Votes Abstained      Broker Non-votes  
 ────────────────────────────────────────────────────────────────────────────
  5,8880,869             54,916               44,599             4,607,827  

Proposal
2

The
Company’s stockholders elected Erez Aminov, Matthew Whalen, Matthew Del Giudice, M. D., Denil Nanji Shekhat, M. D., and Edward MacPherson
as directors of the Company to serve until the next Annual Meeting of Stockholders, or until his respective successor has been duly elected
and qualified, based upon the voting results set forth below.

  Nominee                         Votes For      Votes Abstained      Broker Non-votes  
 ────────────────────────────────────────────────────────────────────────────────────────
  Erez Aminov                     5,862,816              117,568             4,607,827  
  Matthew Whalen                  5,913,451               66,933             4,607,827  
  Matthew Del Giudice, M. D.      5,895,602               84,782             4,607,827  
  Denil Nanji Shekhat, M. D.      5,941,065               39,319             4,607,827  
  Edward MacPherson               5,913,434               66,950             4,607,827  

Proposal
3

The
Company’s stock